AstraZeneca (MEX:AZNN) Cyclically Adjusted PS Ratio: (As of Aug. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:AZNN AstraZeneca PLC MEX:AZNN
88 GF Score
Price MXN1,628.00
GF Value MXN1,722.98
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca  (MEX:AZNN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


AstraZeneca Cyclically Adjusted PS Ratio Related Terms


AstraZeneca Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for AstraZeneca's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Cyclically Adjusted PS Ratio Chart

AstraZeneca Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.51 6.30 5.52 5.02 6.09

AstraZeneca Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.63 5.03 6.09 6.37 5.98

MEX:AZNN vs LLY, JNJ, ABBV: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PS Ratio falls into.


MEX:AZNN
88GF Score
AstraZeneca PLC MEX:AZNN
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

AstraZeneca's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, AstraZeneca's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=86.576/142.3000*142.3000
=86.576

Current CPI (Jun. 2026) = 142.3000.

AstraZeneca Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 43.520 101.500 61.014
201612 45.476 102.200 63.319
201703 40.194 102.700 55.692
201706 36.059 103.500 49.577
201709 44.632 104.300 60.893
201712 44.668 105.000 60.536
201803 37.124 105.100 50.264
201806 39.974 105.900 53.714
201809 39.418 106.600 52.619
201812 49.723 107.100 66.065
201903 42.001 107.000 55.857
201906 42.627 107.900 56.217
201909 48.196 108.400 63.268
201912 47.861 108.500 62.771
202003 56.736 108.600 74.342
202006 55.156 108.800 72.139
202009 55.379 109.200 72.165
202012 56.131 109.400 73.011
202103 56.720 109.700 73.576
202106 62.074 111.400 79.292
202109 67.802 112.400 85.838
202112 78.871 114.700 97.850
202203 72.641 116.500 88.728
202206 69.452 120.500 82.017
202209 70.848 122.300 82.434
202212 70.029 125.300 79.530
202303 62.851 126.800 70.534
202306 62.729 129.400 68.983
202309 64.160 130.100 70.177
202312 65.374 130.500 71.285
202403 67.444 131.600 72.928
202406 75.970 133.000 81.282
202409 85.499 133.500 91.135
202412 99.412 135.100 104.710
202503 89.041 136.100 93.097
202506 87.304 138.400 89.764
202509 89.259 138.900 91.444
202512 90.031 139.900 91.575
202603 88.914 140.800 89.861
202606 86.576 142.300 86.576

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is AstraZeneca (MEX:AZNN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of MXN1,628.00 is trading 5.5% below its estimated GF Value™ of MXN1,722.98.

Key valuation signals for MEX:AZNN:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: MXN1,722.98 vs. price of MXN1,628.00 (5.5% below fair value)
  • GF Score™: 88/100 with 1 warning sign

No single metric tells the full story. See the MEX:AZNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
88GF Score

Get the complete analysis for MEX:AZNN

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,628.00
Price
MXN1,722.98
GF Value